金斯瑞生物科技股份有限公司（01548）于2026年1月5日公布截至2025年12月31日的证券变动月报。报告期内，公司法定股本维持在5,000,000,000股，面值每股0.001美元，注册股本总额仍为5,000,000美元。
\n\n月报显示，公司已发行股本由上月底的2,186,218,520股增至2,186,378,520股，较上月底增加160,000股，库存股数量仍为0股。当月未有股份回购、注销或转为库藏股情形。
\n\n在期权及激励计划方面，公司首次公开发售前购股权计划本月因期权行使新发160,000股，另有620,000股期权失效。该项期权计划于2015年12月7日经股东大会通过，相关执行在报告期内稳步进行。
\n\n综合来看，截至2025年12月31日，公司股本规模较上月有小幅上升。公告由董事孟建革签署，公司表示将继续严格遵守香港联合交易所有限公司《上市规则》的相关规定，确保信息披露真实、准确、完整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.